We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BrightSpring Soars to All-Time High on Quality Strength: Still a Buy?
Read MoreHide Full Article
Key Takeaways
BrightSpring soared 120% year over year, far outperforming AMED, OPCH, and the Medical sector.
BTSG posted Q1 revenue and EPS growth of 14% and 111%, respectively, beating estimates on both fronts.
BTSG's Home Health now has 80% of branches rated 4 stars or higher, with broad quality gains across services.
BrightSpring Health Services (BTSG - Free Report) reached an all-time high of $25.57 on June 9, marking a meteoric 120% stock surge over the past year and in sharp contrast to the declines across the broader medical landscape. While the Medical Services industry and the broader Medical sector have declined 18.2% and 13.6% respectively, BTSG has defied sector trends, significantly outperforming the S&P 500’s 13% gain.
During this period, the company also outperformed competitors like Amedisys (AMED - Free Report) and Option Care Health (OPCH - Free Report) , which rose 2.7% and 12.2%, respectively.
This remarkable rise comes largely on the heels of a market-beating first-quarter 2025 performance and rising investor confidence tied to the company’s improved Home Health star ratings, with over 80% of branches now rated 4 stars or higher.
One-Year Price Performance
Image Source: Zacks Investment Research
Now, it’s time for investors to judge whether there is further upside on the horizon. Let's delve deeper.
Two Major Tailwinds Driving BTSG Stock
Market Beating Q1 Numbers and Upbeat Guidance: BrightSpring’s stellar performance in first-quarter 2025 served as a key catalyst for the recent stock surge. The company posted 14% year-over-year revenue growth and 111% improvement in adjusted EPS, with both metrics exceeding the respective Zacks Consensus Estimate. BrightSpring also reported a 19% rise in adjusted EBITDA, which reinforced management’s confidence in achieving full-year guidance of continued double-digit growth in revenues and EBITDA.
Improving Quality Metrics Across Service Lines: BrightSpring is delivering significant improvements in care quality across its diversified service portfolio, boosting stakeholders' and investors' sentiment. In Home Health, over 80% of branches are now rated 4 stars or higher, with a 60-day hospitalization rate continuing to decline. Patient satisfaction has held strong at approximately 90%. In Hospice, the company delivers 50% more visits and time with patients than the national average, with quality scores at an all-time high. Similarly, Rehabilitation services saw 52% of catastrophic neuro event patients regain independence, while Personal Care hit a record 4.6/5 satisfaction score. High accuracy and speed metrics in Infusion and Pharmacy, such as 99.999% dispense accuracy and 2-hour local deliveries, further highlight BrightSpring’s operational excellence.
Estimates for BrightSpring
The Zacks Consensus Estimate for BrightSpring’s 2025 earnings implies an 82.1% improvement year over year.
Image Source: Zacks Investment Research
BTSG Stock Trading Cheap
BrightSpring stock is currently undervalued compared to its industry, as shown in the chart below.
The company is currently trading at a forward 12-month price-to-sales (P/S) ratio of 0.32, a discount to the broader industry's 0.39. The stock is also trading lower than other industry players like Amedisys (1.23X) and OPCH (0.90X).
However, BTSG is currently above its one-year median of 0.24X, implying that investor sentiment has improved in recent months despite the stock still being undervalued compared to peers.
Image Source: Zacks Investment Research
Buy BrightSpring Now
BrightSpring, currently holding a Zacks Rank #2 (Buy), is demonstrating strong operational momentum across its diversified care segments, including Home Health, Hospice, Rehab, Infusion and Specialty Pharmacy. Notable improvements in quality metrics, such as 4-star-plus CMS ratings across over 80% of Home Health branches, a 9.3 Hospice Care Index and industry-leading patient satisfaction scores are boosting investors' confidence. Trading at a forward P/S ratio well below peers like Amedisys and Option Care Health, BTSG remains undervalued at present.
Image: Bigstock
BrightSpring Soars to All-Time High on Quality Strength: Still a Buy?
Key Takeaways
BrightSpring Health Services (BTSG - Free Report) reached an all-time high of $25.57 on June 9, marking a meteoric 120% stock surge over the past year and in sharp contrast to the declines across the broader medical landscape. While the Medical Services industry and the broader Medical sector have declined 18.2% and 13.6% respectively, BTSG has defied sector trends, significantly outperforming the S&P 500’s 13% gain.
During this period, the company also outperformed competitors like Amedisys (AMED - Free Report) and Option Care Health (OPCH - Free Report) , which rose 2.7% and 12.2%, respectively.
This remarkable rise comes largely on the heels of a market-beating first-quarter 2025 performance and rising investor confidence tied to the company’s improved Home Health star ratings, with over 80% of branches now rated 4 stars or higher.
One-Year Price Performance
Image Source: Zacks Investment Research
Now, it’s time for investors to judge whether there is further upside on the horizon. Let's delve deeper.
Two Major Tailwinds Driving BTSG Stock
Market Beating Q1 Numbers and Upbeat Guidance: BrightSpring’s stellar performance in first-quarter 2025 served as a key catalyst for the recent stock surge. The company posted 14% year-over-year revenue growth and 111% improvement in adjusted EPS, with both metrics exceeding the respective Zacks Consensus Estimate. BrightSpring also reported a 19% rise in adjusted EBITDA, which reinforced management’s confidence in achieving full-year guidance of continued double-digit growth in revenues and EBITDA.
Improving Quality Metrics Across Service Lines: BrightSpring is delivering significant improvements in care quality across its diversified service portfolio, boosting stakeholders' and investors' sentiment. In Home Health, over 80% of branches are now rated 4 stars or higher, with a 60-day hospitalization rate continuing to decline. Patient satisfaction has held strong at approximately 90%. In Hospice, the company delivers 50% more visits and time with patients than the national average, with quality scores at an all-time high. Similarly, Rehabilitation services saw 52% of catastrophic neuro event patients regain independence, while Personal Care hit a record 4.6/5 satisfaction score. High accuracy and speed metrics in Infusion and Pharmacy, such as 99.999% dispense accuracy and 2-hour local deliveries, further highlight BrightSpring’s operational excellence.
Estimates for BrightSpring
The Zacks Consensus Estimate for BrightSpring’s 2025 earnings implies an 82.1% improvement year over year.
Image Source: Zacks Investment Research
BTSG Stock Trading Cheap
BrightSpring stock is currently undervalued compared to its industry, as shown in the chart below.
The company is currently trading at a forward 12-month price-to-sales (P/S) ratio of 0.32, a discount to the broader industry's 0.39. The stock is also trading lower than other industry players like Amedisys (1.23X) and OPCH (0.90X).
However, BTSG is currently above its one-year median of 0.24X, implying that investor sentiment has improved in recent months despite the stock still being undervalued compared to peers.
Image Source: Zacks Investment Research
Buy BrightSpring Now
BrightSpring, currently holding a Zacks Rank #2 (Buy), is demonstrating strong operational momentum across its diversified care segments, including Home Health, Hospice, Rehab, Infusion and Specialty Pharmacy. Notable improvements in quality metrics, such as 4-star-plus CMS ratings across over 80% of Home Health branches, a 9.3 Hospice Care Index and industry-leading patient satisfaction scores are boosting investors' confidence. Trading at a forward P/S ratio well below peers like Amedisys and Option Care Health, BTSG remains undervalued at present.
You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.